β-Catenin and NF-κB co-activation triggered by TLR3 stimulation facilitates stem cell-like phenotypes in breast cancer
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Cancer stem cells (CSCs) are responsible for tumor initiation and progression. Toll-like receptors (TLRs) are highly expressed in cancer cells and associated with poor prognosis. However, a linkage between CSCs and TLRs is unclear, and potential intervention strategies to prevent TLR stimulation-induced CSC formation and underlying mechanisms are lacking. Here, we demonstrate that stimulation of toll-like receptor 3 (TLR3) promotes breast cancer cells toward a CSC phenotype in vitro and in vivo. Importantly, conventional NF-κB signaling pathway is not exclusively responsible for TLR3 activation-enriched CSCs. Intriguingly, simultaneous activation of both β-catenin and NF-κB signaling pathways, but neither alone, is required for the enhanced CSC phenotypes. We have further identified a small molecule cardamonin that can concurrently inhibit β-catenin and NF-κB signals. Cardamonin is capable of effectively abolishing TLR3 activation-enhanced CSC phenotypes in vitro and successfully controlling TLR3 stimulation-induced tumor growth in human breast cancer xenografts. These findings may provide a foundation for developing new strategies to prevent the induction of CSCs during cancer therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091 · cited 1×
“Triple-negative breast cancer and inflammatory breast cancer represent two of the most aggressive forms of human breast cancer, as characterized by their unique molecular profiles, aggressive behavior, and distinctive metastasis patterns.(29,30) Significantly, we found that TLR3 expression was also present in SUM149,…”
BackgroundA cell initiating human acute myeloid leukaemia after transplantation into SCID mice
Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M. A., & Dick, J. E. (1994) · Nature · doi:10.1038/367645a0 · Cited by 4,783
Tumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668 · cited 2×
“We further examined whether poly(I:C)-treated breast cancer cells became more resistant to chemotherapeutic drugs, another known CSC property.(8,9) As expected, poly(I:C)-treated cells were more resistant than controls to two commonly used chemotherapeutic drugs, paclitaxel and doxorubicin (Figure 2c).”
BackgroundInflammation-induced cancer: Crosstalk between tumours, immune cells and microorganisms
Elinav, E., Nowarski, R., Thaiss, C. A., Hu, B., Jin, C., & Flavell, R. A. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3611 · Cited by 2,000
Wnt signaling mediates regional specification in the vertebrate face
Brugmann, S. A., Goodnough, L. H., Gregorieff, A., Leucht, P., ten Berge, D., Fuerer, C., Clevers, H., Nusse, R., & Helms, J. A. (2007) · Development · doi:10.1242/dev.005132 · Cited by 213
Cited by
Lipid Desaturation Is a Metabolic Marker and Therapeutic Target of Ovarian Cancer Stem Cells
Li, J., Condello, S., Thomes-Pepin, J., Ma, X., Xia, Y., Hurley, T. D., Matei, D., & Cheng, J.-X. (2017) · Cell Stem Cell · doi:10.1016/j.stem.2016.11.004 · Cited by 579
Crosstalk between Wnt/β-Catenin and NF-κB Signaling Pathway during Inflammation
Ma, B., & Hottiger, M. O. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00378 · Cited by 563
Stem cell programs in cancer initiation, progression, and therapy resistance
Huang, T., Song, X., Xu, D., Tiek, D., Goenka, A., Wu, B., Sastry, N., Hu, B., & Cheng, S.-Y. (2020) · Theranostics · doi:10.7150/thno.41648 · Cited by 524
Vallée, A., & Lecarpentier, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00745 · Cited by 374
Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances
Xue, C., Chu, Q., Shi, Q., Zeng, Y., Lu, J., & Li, L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02142-w · Cited by 281
Self-citationHarnessing innate immune pathways for therapeutic advancement in cancer
Hu, A., Sun, L., Lin, H., Liao, Y., Yang, H., & Mao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01765-9 · Cited by 255
Extracellular matrix stiffness dictates Wnt expression through integrin pathway
Du, J., Zu, Y., Li, J., Du, S., Xu, Y., Zhang, L., Jiang, L., Wang, Z., Chien, S., & Yang, C. (2016) · Scientific Reports · doi:10.1038/srep20395 · Cited by 207
Vallée, A., Lecarpentier, Y., Guillevin, R., & Vallée, J.-N. (2017) · Oncotarget · doi:10.18632/oncotarget.21234 · Cited by 204
“In breast cancer, β-catenin/TCF and NF-κB signaling activate each other in a synergistic manner [196].”
BackgroundJia, D., Li, L., Andrew, S., Allan, D., Li, X., Lee, J., Ji, G., Yao, Z., Gadde, S., Figeys, D., et al. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.319 · Cited by 105
Self-citation
Metadata
- Authors
- Jia, D., Yang, W., Li, L., Liu, H., Tan, Y., Ooi, S., Chi, L., Filion, L. G., Figeys, D., & Wang, L.
- Venue
- Cell Death & Differentiation
- Published
- 2014-09-26
- Volume
- 22
- Issue
- 2
- Pages
- 298-310
- ISSN
- 1350-9047 (ISSN-L)
- 1476-5403
- OpenAlex
- W2024149236
- Cited by
- 113
- References
- 6
- FWCI
- 3.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.